Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference
July 07 2021 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a
biopharmaceutical company, today announced that Jill C. Milne,
Ph.D., Chief Executive Officer, will present a corporate overview
and provide information on its lead program QLS-215, which is in
preclinical development for the treatment of hereditary angioedema,
at the upcoming virtual Ladenburg Thalmann Healthcare Conference.
The presentation will take place on Tuesday, July 13th, 2021 at
12:30pm ET.
A webcast of the presentation will be available at the following
link: https://wsw.com/webcast/ladenburg7/catb/2378558, and will
also be available in the investors section of the Company’s
website, www.catabasis.com, and will be archived for 30 days
following the presentation.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope with
life-changing therapies to patients and families affected by rare
and niche diseases. Our lead program, QLS-215, is a monoclonal
antibody inhibitor of plasma kallikrein in preclinical development
for the treatment of hereditary angioedema.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210707005084/en/
Catabasis: Investor
relations: Andrea Matthews investors@catabasis.com
Media: Elizabeth Higgins media@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Aug 2023 to Aug 2024